{
  "symbol": "A",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.2266,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.153
  },
  "top_positive": [
    {
      "sent": "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of October\u00a031, 2023 were as follows: Fair Value Measurement at October 31, 2023 Using October 31, 2023 Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level\u00a03) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 994 $ 994 $ \u2014 $ \u2014 Derivative instruments (foreign exchange contracts) 19 \u2014 19 \u2014 Long-term Trading securities 36 36 \u2014 \u2014 Other investments 26 \u2014 26 \u2014 Total assets measured at fair value $ 1,075 $ 1,030 $ 45 $ \u2014 Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 2 $ \u2014 $ 2 $ \u2014 Contingent consideration 1 \u2014 \u2014 1 Long-term Deferred compensation liability 36 \u2014 36 \u2014 Total liabilities measured at fair value $ 39 $ \u2014 $ 38 $ 1 Financial assets and liabilities measured at fair value on a recurring basis as of October\u00a031, 2022 were as follows: Fair Value Measurement at October 31, 2022 Using October 31, 2022 Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level\u00a03) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 492 $ 492 $ \u2014 $ \u2014 Derivative instruments (foreign exchange contracts) 31 \u2014 31 \u2014 Long-term Trading securities 31 31 \u2014 \u2014 Other investments 23 \u2014 23 \u2014 Total assets measured at fair value $ 577 $ 523 $ 54 $ \u2014 Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ \u2014 $ 5 $ \u2014 Contingent consideration 66 \u2014 \u2014 66 Long-term Deferred compensation liability 31 \u2014 31 \u2014 Contingent consideration 1 \u2014 \u2014 1 Total liabilities measured at fair value $ 103 $ \u2014 $ 36 $ 67 Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level\u00a01 of the fair value hierarchy.",
      "score": 0.9949
    },
    {
      "sent": "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of October\u00a031, 2023 were as follows: Fair Value Measurement at October 31, 2023 Using October 31, 2023 Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level\u00a03) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 994 $ 994 $ \u2014 $ \u2014 Derivative instruments (foreign exchange contracts) 19 \u2014 19 \u2014 Long-term Trading securities 36 36 \u2014 \u2014 Other investments 26 \u2014 26 \u2014 Total assets measured at fair value $ 1,075 $ 1,030 $ 45 $ \u2014 Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 2 $ \u2014 $ 2 $ \u2014 Contingent consideration 1 \u2014 \u2014 1 Long-term Deferred compensation liability 36 \u2014 36 \u2014 Total liabilities measured at fair value $ 39 $ \u2014 $ 38 $ 1 Financial assets and liabilities measured at fair value on a recurring basis as of October\u00a031, 2022 were as follows: Fair Value Measurement at October 31, 2022 Using October 31, 2022 Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level\u00a03) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 492 $ 492 $ \u2014 $ \u2014 Derivative instruments (foreign exchange contracts) 31 \u2014 31 \u2014 Long-term Trading securities 31 31 \u2014 \u2014 Other investments 23 \u2014 23 \u2014 Total assets measured at fair value $ 577 $ 523 $ 54 $ \u2014 Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ \u2014 $ 5 $ \u2014 Contingent consideration 66 \u2014 \u2014 66 Long-term Deferred compensation liability 31 \u2014 31 \u2014 Contingent consideration 1 \u2014 \u2014 1 Total liabilities measured at fair value $ 103 $ \u2014 $ 36 $ 67 Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level\u00a01 of the fair value hierarchy.",
      "score": 0.9949
    },
    {
      "sent": "Options Outstanding Weighted Average Exercise Price (in thousands) Outstanding at October 31, 2022 1,097 $ 94 Granted 269 $ 147 Exercised ( 249 ) $ 41 Cancelled ( 37 ) $ 142 Outstanding at October 31, 2023 1,080 $ 118 The options outstanding and exercisable for equity share-based payment awards at October\u00a031, 2023 were as follows: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Number Exercisable Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value (in thousands) (in years) (in thousands) (in thousands) (in years) (in thousands) $ 40.01 -\u00a0$ 50.00 210 1.0 $ 41 13,088 210 1.0 $ 41 13,088 $ 100.00 - $ 110.00 311 7.0 $ 110 \u2014 177 7.0 $ 110 \u2014 $ 110.01 - $ 150.00 319 8.8 $ 143 \u2014 40 8.3 $ 136 \u2014 $ 150.01 & Over 240 8.0 $ 161 \u2014 80 8.0 $ 161 \u2014 1,080 6.6 $ 118 $ 13,088 507 4.8 $ 92 $ 13,088 The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, based on the company's closing stock price of $ 103.37 at October\u00a031, 2023, which would have been received by award holders had all award holders exercised their awards that were in-the-money as of that date.",
      "score": 0.9944
    }
  ],
  "top_negative": [
    {
      "sent": "If we fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity; investigations or notices of non-compliance, fines, injunctions, and civil or criminal penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; suspension or revocation of our license to operate; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products.",
      "score": -0.9524
    },
    {
      "sent": "If we fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity; investigations or notices of non-compliance, fines, injunctions, and civil or criminal penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; suspension or revocation of our license to operate; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products.",
      "score": -0.9524
    },
    {
      "sent": "If we fail to comply with FDA and other applicable regulatory requirements or are perceived to potentially have failed to comply, we may face, among other things, warning letters; adverse publicity; investigations or notices of non-compliance, fines, injunctions, and civil or criminal penalties; import or export restrictions; partial suspensions or total shutdown of production facilities or the imposition of operating restrictions; suspension or revocation of our license to operate; increased difficulty in obtaining required FDA clearances or approvals or foreign equivalents; seizures or recalls of our products or those of our customers; or the inability to sell our products.",
      "score": -0.9524
    }
  ],
  "forward_snippets": [
    "As a leader in liquid chromatography, we continue to expand our application space with new HPLC columns, new services and diagnostics offerings and ongoing instrument and software product enhancements.",
    "Research and Development We anticipate that we will continue to have significant research and development expenditures in order to maintain our competitive position with a continuing flow of innovative, high-quality products and services.",
    "We remain committed to invest significantly in research and development and have focused our development efforts on key strategic opportunities to align our business with available markets and position ourselves to capture market share.",
    "Backlog We believe that backlog is not a meaningful indicator of future business prospects for our business segments since a significant portion of our revenue for a given quarter is derived from the current quarter's orders.",
    "Therefore, we believe that backlog information is not material to an understanding of our business."
  ]
}